Health
Excellent outcomes reported for first targeted frontline therapy for high-risk pediatric Hodgkin lymphoma – Newswise
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma.
A new kind of therapy
Brentuximab vedotin is an anti-CD30 antibody drug conjugate. The drug, which is already approved to treat adults with Hodgkin lymphoma, is targeted specifically to Hodgkin Reed Sternberg cells (cancer cells in Hodgkin lymphoma). Brentuximab vedotin delivers the medicine directly where it is needed.
“I think of brentuximab vedotin as a smart drug,” said first and corresponding author Monika Metzger, M.D., St. Jude Departments of Oncology and Global Pediatric Medicine. “Unlike conventional chemotherapy, which…
-
Noosa News13 hours agoMan dies in Brisbane crash, women and girl rushed to hospital
-
Noosa News19 hours agoChilling new details emerge in terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General22 hours agoProductivity summit ends day two with progress on rules changes to boost housing supply
-
General24 hours agoRed tape on chopping block in bid to build homes faster